Introduction
============

Amplification of the human epidermal growth factor receptor 2 (*HER2*) gene and overexpression of the HER2 protein is found in a number of human cancers, including breast and gastroesophageal cancer. The gene for *HER2* (also known as ErbB-2, c-erbB2 or Her2/neu) is a proto-oncogene located on the chromosome 17q. This gene encodes a 185-kDa transmembrane tyrosine kinase receptor protein that is a member of the human epidermal growth factor receptor family, which consists of HER1 (EFGR), HER2, HER3, and HER4. HER2 forms both homo- and heterodimers with the different members of the HER family, thereby serving as a critical dimerization partner, which leads to activation of downstream signaling pathways associated with cell proliferation, differentiation, survival and angiogenesis [@B1], [@B2]. Amplification of the *HER2* gene in gastric cancer was first described in 1986, and since then a large number of studies have confirmed this finding [@B2], [@B3].

In both gastroesophageal and breast cancer HER2 serves as an important therapeutic target. For gastroesophageal cancer, the clinical utility of HER2 targeted therapy was demonstrated in the ToGA trial, in which HER2-positive patients with advanced disease were randomized to receive 5-FU/capecitabine and cisplatin, either alone or in combination with trastuzumab (Herceptin^®^, Roche/Genentech). A clinically relevant and statistically significant gain in overall survival was observed in patients who received the combined treatment of trastuzumab plus chemotherapy [@B4]. Based on the positive results from the ToGA trial, HER2 testing of gastroesophageal cancer patients is now routinely performed in most pathology laboratories where both immunohistochemistry (IHC) and fluorescence *in situ* hybridization (FISH) assays serve as companion diagnostics for trastuzumab. In general, a positive HER2 status is found in approximately 15% to 20% of patients with gastroesophageal cancer [@B2].

Due to the differences in tumor biology, HER2 testing in gastroesophageal cancer with IHC and FISH differs from breast cancer. The gastric cancer tissue more frequently shows HER2 heterogeneity and incomplete membrane staining, and consequently a specific gastric cancer scoring system is used [@B5],[@B6],[@B7]. In the ToGA trial, HER2 positivity was defined as being either IHC3+ or FISH+ (*HER2*/CEN-17 ≥ 2.0), and based on the results from this study, a specific testing algorithm was developed. Here, IHC is regarded as the primary test, with FISH as a reflex test in borderline cases of IHC2+. However, as almost all patients in the ToGA trial had a FISH and IHC test performed, the US FDA recommends that both IHC2+ and IHC3+ cases are reflex tested with FISH [@B8].

When the *HER2* FISH pharmDx (Dako) assay used during the ToGA trial, was developed for determination of *HER2* gene amplification in gastroesophageal cancer specimens, differences in the *HER2* signal distribution at the tissue level was observed as compared to breast cancer. In the gastroesophageal cancer tissue, the distribution of *HER2* signals can be either homogeneous or heterogeneous, and further the heterogeneous distribution can be categorized as either focal or mosaic. These phenotypical characteristics are briefly described in the instruction for use (IFU) for the *HER2*IQFISH pharmDx™ assay, and here, it is stated that the different *HER2* signal distribution patterns should be recognized in relation to the selection of tumor area for the signal enumeration [@B9]. If and how the signal distribution influences the *HER2* amplification status has not been studied so far. Here, we report a study aimed to investigate whether a link between *HER2* amplification and the different signal distribution patterns in tumor specimens from patients with gastroesophageal cancer exists. Furthermore, we raise the hypothesis that the signal distribution patterns observed with FISH might be related to different subpopulations of *HER2*positive cancer cells.

Materials and Methods
=====================

Tissue Specimens
----------------

A total of 140 formalin-fixed, paraffin-embedded (FFPE) gastroesophageal adenocarcinoma specimens were included in the study, which covered both resections and biopsies. All specimens were residual, de-identified FFPE blocks originating from individual patients and were prepared according to the IFU for the *HER2* IQFISH pharmDx assay and subsequently cut in serial sections of 4μm and mounted on glass slides [@B9]. The specimens were obtained from commercial providers or local hospitals and the patient identities were not traceable. For each specimen, a pathologist identified the tumor area, which was indicated directly on a hematoxylin and eosin stained slide. Inclusion criteria were not related to signal distribution in the specimens, but acceptable tumor morphology and signal quality was required for inclusion. Additionally, specimens were included to represent comparable numbers of *HER2* amplified and non-amplified cases as well as comparable numbers within the HER2 protein expression levels 0/1+, 2+ and 3+ (see Table [1](#T1){ref-type="table"}) as determined by HercepTest™ according to the manufacturer\'s recommendations. The study was conducted in accordance with the current version of the World Medical Association Declaration of Helsinki. The study protocol was not submitted to an Ethics Committee (EC) as this type of analytical study in Denmark is exempt from EC approval. The specimens in the study were part of an internal validation study where the *HER2*IQFISH pharmDx assay was compared to an automated version of the assay (Dako Omnis) [@B10].

HER2 IQFISH pharmDx and fluorescence microscopy
-----------------------------------------------

The gastroesophageal tumor specimens were stained manually with the *HER2*IQFISH pharmDx assay, which contains all key reagents required to complete a FISH procedure. Briefly, the cut specimen sections were exposed to heat pre-treatment using a microwave oven, and were then digested with pepsin at 37 °C to prepare the tissue for probe hybridization. Co-denaturation of probe and tissue target DNA was performed for 10 minutes at 66 °C followed by hybridization at 45 °C for 90 minutes using a Hybridizer (Agilent Technologies). The hybridization was performed using the RTU *HER2*/CEN-17 FISH Probe Mix based on a combination of a Texas Red-labeled DNA probe (*HER2*) and a fluorescein-labeled PNA probe (CEN-17). Following hybridization, specimen sections were subjected to stringent wash at 63 °C for 10 minutes before dehydration and drying. Dried slides were subsequently mounted using Fluorescence Mounting Medium containing 4\',6-diamidino-2-phenylindole (DAPI) and cover slipped. The *HER2* IQFISH stained slides were evaluated and enumerated using a fluorescence microscope equipped with 20×, 40× and 100× objectives and appropriate fluorescence filters for detection of the Texas Red labeled *HER2* DNA and fluorescein labeled CEN-17 PNA probe signals [@B9], [@B11]. Images were captured on an Olympus BX63 fluorescence microscope equipped with a DP73 camera using an Omega fluorescein / Texas Red dual band filter.

Assessment of Tissue Specimens
------------------------------

The assessment of the gene signal distribution was performed by locating the tumor within the context of the H&E stained slide and evaluating the same area on the FISH stained slide and subsequently determine the overall signal distribution (homogenous or heterogeneous). In case of heterogeneous signal distribution, it was then determined whether focal or mosaic distribution was present. The *HER2*/CEN-17 ratio was calculated based on the enumeration of 20 nuclei from the invasive tumor area. Based on this ratio, the specimens were categorized into amplified (*HER2*/CEN-17 ≥ 2.0) or non-amplified (*HER2*/CEN-17 \< 2.0) HER2 status. Specimens with a ratio between 1.8 and 2.2 (borderline cases) were subjected to enumeration of additional 40 nuclei and the ratio was then recalculated for these 40 nuclei to determine if *HER2*amplification was present or not. In every stained section the presence of 1-2 clearly visible red and green signals in normal cells served as an internal quality control of the staining reaction [@B9], [@B11].

Results
=======

The gastric cancer specimens examined in this study are primarily from the stomach region (81%) with the remaining specimens from the gastroesophageal junction (19%) (Table [1](#T1){ref-type="table"}). The majority of specimens are resections (93%) and a minor fraction are biopsies (7%) (Table [1](#T1){ref-type="table"}).

Examinations of gastroesophageal cancer tissues revealed that the distribution of fluorescent *HER*2 signals following *HER2*/CEN-17 FISH staining was not uniform and different signal distribution patterns were identified as illustrated by the drawings and fluorescence images from gastroesophageal specimens in Figure [1](#F1){ref-type="fig"}. These signal distribution patterns can be divided into the subgroups homogeneous and heterogeneous. Homogeneous signal distribution is defined by the same level of *HER*2 gene copies in all tumor nuclei (Figure [1](#F1){ref-type="fig"}, A and B), whereas, heterogeneous signal distribution is characterized by a variable number of *HER*2 gene copies in the tumor nuclei of a specimen. The heterogeneous signal distribution pattern can be subdivided into a focal (Figure [1](#F1){ref-type="fig"}C) and a mosaic (Figure [1](#F1){ref-type="fig"}D) pattern depending on whether the nuclei of tumor cells with variable *HER2* gene copies are grouped together or are interspersed in the tumor tissue, respectively.

The gastric cancer specimens were inspected for the *HER2*signal distribution in the tumor part according to the definitions described and illustrated above. A total of 83 specimens had heterogeneous *HER2* signal distribution with 62 being focal and 21 of the mosaic type (Table [2](#T2){ref-type="table"}). Homogeneous signal distribution was observed in 57 specimens (Table [2](#T2){ref-type="table"}). The *HER2*/CEN-17 ratios were determined for all specimens using the US FDA approved *HER2* IQFISH pharmDx according to the manufacturer\'s instructions (see Materials and Methods section) [@B9]. To illustrate *HER2*/CEN-17 ratios in the three signal distribution groups plots were made for all specimens (Figure [2](#F2){ref-type="fig"}A) and for the subset with a maximum *HER2*/CEN-17 ratio at 4 (Figure [2](#F2){ref-type="fig"}B). In both plots in Figure [2](#F2){ref-type="fig"} red color indicates an amplified HER2 status and a blue color indicates non-amplified HER2 status. Additionally, descriptive values for the *HER2*/CEN-17 ratio (mean, median, 95% confidence intervals (CI95%), and N) in each signal distribution group is shown in Table [2](#T2){ref-type="table"}. We also observed a difference between the *HER2*/CEN-17 ratio in tissue of gastric versus esophageal origin. Mean *HER2*/CEN-17 ratio in the gastric specimens was 5.20 (CI95%: 3.96 - 6.44) and 3.03 (CI95%: 2.12 - 3.95) in the esophageal specimens (data not shown).

The concordance between *HER2* FISH and HER2 IHC for the gastric cancer specimens can be calculated from the data in Table [1](#T1){ref-type="table"}. These data show a 95.9% (CI95%: 86.3-98.9) agreement between *HER2* non-amplified and IHC 0/1+ groups and a 93.0% (CI95%: 81.4-97.6) agreement between *HER2* amplified and the IHC 3+ group. Furthermore, overall agreement for the 0/1+ and 3+ groups can be calculated at 94.6% (CI95%: 87.9-97.7).

From Figure [2](#F2){ref-type="fig"} and Table [2](#T2){ref-type="table"} a clear tendency can be observed towards a higher *HER2*/CEN-17 ratio in the heterogeneous focal HER2 signal distribution group of the gastric cancer specimens studied. Comparison of mean *HER2*/CEN-17 ratios between the focal heterogeneous group and the mosaic heterogeneous and homogeneous groups indicated an elevated *HER2*/CEN-17 ratio in the focal heterogeneous distribution group. By data analysis in JMP 12.2 it was observed that *HER2*/CEN-17 ratios were not well described by the normal distribution even following Box Cox transformation. Therefore, for comparison of mean *HER2*/CEN-17 ratios in the three distribution groups, robust data analyses using nonparametric testing with ANOM (Analysis of Means with transformed ranks) and the Wilcoxon test were performed. ANOM of transformed ranks showed that the mean *HER2*/CEN-17 ratios in each of the three signal distribution groups differed significantly from the overall mean (p\<0.002). In addition, Wilcoxon tests indicated that the mean *HER2*/CEN-17 ratio of the heterogeneous focal group differed significantly from the heterogeneous mosaic group and the homogeneous group (p\<0.0001). Wilcoxon tests also revealed that the *HER2*/CEN-17 ratio mean of the heterogeneous mosaic group differed significantly from the homogeneous group (p\<0,0005). Therefore, the data obtained in this study shows that *HER2*/CEN-17 ratios in gastric cancer specimens with focal heterogeneous HER2 signal distribution are significantly higher compared to gastric cancer specimens with homogeneous or mosaic heterogeneous HER2 signal distribution.

To clarify if the *HER2*/CEN-17 ratio differences between signal distribution groups were mirrored by differences in HER2 status, cross-tabulation of HER2 status in the three groups are presented (Table [3](#T3){ref-type="table"}). Chi-square test (Pearson) of the hypothesis that the frequency of *HER2* non-amplified and *HER2* amplified specimens are identical in the signal distribution groups revealed a low p value (p\<0.0001), indicating that these frequencies are significantly different. In addition, comparison using Fisher\'s test between individual signal distribution groups revealed significant difference between HER2 status of the heterogeneous focal and heterogeneous mosaic distribution groups (p\<0.0001) as well as between the heterogeneous focal and homogeneous signal distribution groups (p\<0.0001). Between the heterogeneous mosaic and homogeneous signal distribution groups a high p value (p=0.57) was found, indicating no difference in HER2 status between these groups.

Discussion
==========

Different *HER2* signal distribution patterns can be observed in tissue specimens from patients with gastroesophageal cancer; however, what this means in relation to *HER2* amplification has not been studied systematically so far. In the current study, we investigated the relationship between *HER2* amplification and the different signal distribution patterns in tumor specimens from patients with gastroesophageal cancer.

The 140 tissue specimens in the study sample mainly originated from patients with gastric cancer; however, approximately 20% of these came from patients with gastric esophageal junction cancer. The proportion of *HER2*amplified specimens in the study sample was 45%, which is somewhat higher than the approximately 15% to 20% that would have been expected from an unselected population of patients with gastroesophageal cancer [@B2]. The reason for the high proportion of HER2 positive specimen in the study sample is that originally, they were selected for a validation study where a certain proportion of both HER2 positive and negative specimens were required [@B10]. The high proportion of HER2 positive specimens in the current study sample should be considered an advantage for the purpose of the study. Had the prevalence of HER2 positive specimens been lower it would have been more difficult to obtain significant results. The IHC HER2 status were known for all specimens included in the study, and when calculating the agreement between IHC and FISH the results were well in line with a recent reported meta-analysis based on data from more than 12,000 gastric cancer patients [@B12].

Based on the current study sample we demonstrate that *HER2* amplification in gastroesophageal cancer is closely linked to the focal heterogeneous signal distribution. Nearly 94% of all the specimens that had a *HER2*/CEN-17 ≥ 2.0 was found in the focal heterogeneous group. Using Fisher\'s test, the HER2 status for this group was found to be highly significantly different compared to the heterogeneous mosaic and homogeneous groups. Furthermore, the mean *HER2*/CEN-17 ratio for the focal heterogeneous group was 8.75 (CI95%: 6.87 - 10.63), which is several times higher than the mean *HER2*/CEN-17 ratio for the two other groups. For the heterogeneous mosaic and homogeneous groups, the mean *HER2*/CEN-17 ratios were 1.53 (CI95%: 1.45 - 1.61) and 1.70 (CI95%: 1.22 - 2.18), respectively. Both the ANOM and the Wilcoxon tests showed that the mean *HER2*/CEN-17 ratio for the focal heterogeneous group was highly significantly different compared to the two other signal distribution groups. To the best of our knowledge, it is the first time that such strong link between *HER2*amplification and the signal distribution pattern has been shown in gastroesophageal cancer. A relationship between focal *HER2* amplification and gastroesophageal cancer has been described sporadically in other studies but not previously while using the definitions of focal, mosaic and homogeneous signal distributions [@B13], [@B14].

HER2 overexpression is a well described driver of carcinogenesis that has been shown to impair cellular organization by disrupting cell polarity and cellular adhesion [@B15], to promote cellular migration and invasion [@B16], and also to lead to uncontrolled proliferation by interference with cell cycle regulators such as cyclin D1 and p27 [@B17]. There is also indication that HER2 overexpression via HER2-HER3 heterodimer formation leads to transformation involving activation of the PI3K/Akt and MAPK pathway [@B18], [@B19]. The effect of HER2 overexpression on cancer cell phenotype and growth properties in tumors has been shown to depend on activation of SH2 domain containing proteins such as src-kinase, that is known to regulate integrin signaling and focal adhesions [@B20]. Interestingly, src kinase inhibition in HER2 overexpressing breast tumor cells has revealed different growth phenotypes ranging from inhibition of invasiveness to complete growth inhibition [@B19].

Intra tumor heterogeneity and tumor aneuploidy are important mechanisms for development of drug resistance [@B21], and tumor characterization or stratification by *in situ* hybridization techniques offer the possibility to combine genetic/chromosomal information with spatial phenotypic characteristics of tumors. In this dataset, the observation that a characteristic tumor growth pattern in gastric cancer is linked to *HER2*amplification could suggest that the HER2 positive tumor cells are mainly dominant with respect to the focal growth pattern. In a recent study of intra-tumor heterogeneity of breast cancers, the *HER2*amplified and *HER2* non-amplified genetic components were investigated using copy number profiling and sequencing [@B22]. It was found that *HER2*gene amplification was heterogeneously distributed within a given tumor, and it was also observed that alternative driver genetic alterations between the *HER2*amplified and *HER2* non-amplified part of a given tumor differed. Therefore, we speculate that the intra-tumor phenotypic difference in cancer growth exemplified by the variable signal distribution patterns of gastric cancer cells could be attributed to underlying genetic heterogeneity.

If we assume that the different signal distribution patterns represent different subtypes of HER2 positive cells, the next step would be to speculate about the clinical impact. Currently, trastuzumab is the only approved HER2-targeted drug for treatment of HER2 positive gastroesophageal cancer, and far from all patients respond adequately [@B4], [@B23], [@B24]. In order to achieve a higher predictive value of the current ISH tests, determination of the signal distribution patterns might be a supplement that could increase the value of these tests. Likewise, as a number of new HER2 targeted compounds, both small molecules as well as antibodies, are under development, the signal distribution patterns might help to improve the predictability of these new drugs [@B8]. These questions will need to be addressed in future studies.

As the current study was performed based on anonymized specimens no or very few clinicopathological patient characteristics have been available. This should be considered a drawback and the possibilities of doing different exploratory analyses are limited. However, taken these limitations into consideration the study has been able to demonstrate a clear relationship between *HER2* amplification and the focal heterogeneous signal distribution in patients with gastroesophageal cancer. Furthermore, based on the phenotypical characteristics of the different signal distribution patterns we have raised the hypothesis that the related HER2 positive tumor cells might belong to different subpopulations. In the literature, it has been suggested that HER2 overexpression and/or amplification might be one of the molecular abnormalities linked to the development of gastric cancer [@B19], [@B25], [@B26]. If and how the *HER2*signal distribution patterns play a role in cancer development further research may show.
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![Images and schematic illustrations exemplify the different signal distribution patterns identified in gastroesophageal cancer specimens analyzed with *HER2* IQFISH pharmDx™. A) *HER*2 non-amplified tumor cells. B) *HER*2 amplified tumor cells with homogeneous signal distribution. C) *HER2* amplified tumor cells with heterogeneous focal signal distribution with grouped amplified tumor cells surrounded by non-amplified tumor cells. D) Amplified tumor cells with a heterogeneous mosaic signal distribution pattern where the *HER*2 amplified and non-amplified tumors cells are interspersed. The red dots indicate *HER*2 signals and green dots indicate CEN-17 signals. Amplified cells are indicated in dark blue in the schematic and non-amplified are light blue. Images are generated at 400x.](jcav08p1517g001){#F1}

![Plot of *HER2*/CEN-17 ratios (N=140) determined by *HER2* IQFISH pharmDx™ staining of the gastric cancer specimens by signal distribution group. All specimens are illustrated in A) and in B) specimens up to a *HER2*/CEN-17 ratio of 4.0 are plotted. Blue data points indicate non-amplified HER2 status and red data points indicate amplified HER2 status. Random jittering by SAS JMP was included to better visualize overlying or nearby data points.](jcav08p1517g002){#F2}

###### 

Tabulation of gastric cancer specimen location, type and HercepTest score by HER2 status. The HER2 status was determined according to the manufacturer\'s instructions for manual *HER2* IQFISH pharmDx.

                                HER2amplified   HER2non-amplified   N
  ----------------------------- --------------- ------------------- -----
  **Specimen location**                                             
  Gastric                       52              62                  114
  Gastric esophageal junction   11              15                  26
  All specimen locations        63              77                  140
  **Specimen type**                                                 
  Biopsy                        4               6                   10
  Resection                     59              71                  130
  All specimen types            63              77                  140
  **HercepTest score**                                              
  0                             2               32                  34
  1+                            0               15                  15
  2+                            21              27                  48
  3+                            40              3                   43
  All HercepTest scores         63              77                  140

###### 

Mean, median, 95% confidence limits and N for *HER2*/CEN-17 ratios by signal distribution pattern. The *HER2*/CEN-17 ratio was determined according to the manufacturer\'s instructions for manual *HER2* IQFISH pharmDx.

                         *HER2*/CEN-17 ratio                         
  ---------------------- --------------------- ------ -------------- -----
  Focal heterogeneous    8.75 ^1,2^            6.32   6.87 - 10.63   62
  Mosaic heterogeneous   1.53 ^1,3^            1.53   1.45 - 1.61    21
  Homogeneous            1.70 ^1^              1.33   1.22 - 2.18    57
  All                    4.80                  1.69   3.77 - 5.83    140

1\) *HER2*/CEN-17 ratio mean significantly different from the overall ratio mean by ANOM for transformed ranks (p\<0.002).2) *HER2*/CEN-17 ratio mean significantly different from the ratio means of mosaic heterogeneous and homogeneous group by Wilcoxon (p\<0.0001). 3) *HER2*/CEN-17 ratio mean significantly different from the ratio mean of the homogeneous group by Wilcoxon (p\<0.0005).

###### 

Tabulation of number of gastric cancer specimens in HER2 signal distribution group by HER2 FISH status. Number in parenthesis indicate percent observed in signal distribution group.

  --------------------------------------------------------------
                             HER2\         HER2\           N
                             amplified     non-amplified   
  -------------------------- ------------- --------------- -----
  Heterogeneous-focal ^1^    59 (93.7%)    3 (3.9%)        62

  Heterogeneous-mosaic ^2^   0 (0.0%)      21 (27.3%)      21

  Homogeneous                4 (6.3%)      53 (68.8%)      57

  Total                      63 (100.0%)   77 (100.0%)     140
  --------------------------------------------------------------

Frequency of HER2 status different between groups by Pearson Chi-square test (p\<0.0001)1) HER2 status significantly different to Heterogeneous mosaic and Homogeneous group by Fishers test (p\<0.0001).2) HER2 status not significantly different to Homogeneous group by Fishers test (p=0.57).
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